We based our approach on previously published studies that modeled KRAS-induced arteriovenous malformations (AVMs) by treating cells with a control vector or a vector expressing mutant KRAS (Nikolaev et al., 2018; Fish et al., 2020). The gene discussed is KRAS; the disease is arteriovenous hemangioma/malformation.